No Abstract

No Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects around 30% of the global population. Studies suggest that MASLD is associated with compromised brain health and cognitive dysfunction, initiating a growing interest in exploring the liver–brain axis mechanistically within MASLD pathophysiology. With the prevalence of MASLD increasing at an alarming rate, leaving a large proportion

No Abstract

BackgroundInternational guidelines suggest screening for advanced fibrosis due to metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes, but how to implement these guidelines in clinical care remains unclear. We hypothesise that examination with VCTE could be implemented simultaneously with retina scanning with a high acceptance rate in people with type 2 diabetes

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Further to the Expression of concern The Lancet Gastroenterology & Hepatology issued in September 20241 for an Article presenting country, regional, and global estimates of lactose malabsorption,2 the Editors worked with the authors of the paper to determine whether further data included in the paper did not fully meet the study's stated eligibility criteria. Estimates for a substantial number of countries

In this Comment,1 the authors cite and interpret data based on an Article we now know to be unreliable and that has now been retracted.2 The Committee on Publication Ethics advises that, in such circumstances, the linked Comment should also be retracted to avoid any misunderstanding among readers. We are therefore retracting this Comment.

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Janssen HLA, Lim Y-S, Lampertico P, et al. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2024; 9: 718–33—In this Article, the label for previous other oral antiviral in figure 3B should have read 0·04; the label for previous

Click B, Holubar SD. Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? Lancet Gastroenterol Hepatol 2024; 9: 774–75—In this Comment, the last sentence of the third paragraph should read “While previously described extended mesenteric excision approaches incorporate a high ligation of the ileocolic pedicle, van der Does de Willebois and colleagues assess a modified

Section snippets Subcutaneous guselkumab for Crohn's diseaseInduction with subcutaneous guselkumab—a dual acting IL-23p19 subunit inhibitor—was safe and efficacious in patients with Crohn's disease according to the phase 3 GRAVITI study presented by Remo Panaccione (Calgary, AB, Canada). 347 patients with moderate-to-severe Crohn's disease with an inadequate response or intolerance to oral corticosteroids

Section snippets Semaglutide for MASHSemaglutide 2·4 mg once a week demonstrated significantly greater improvements in histology and fibrosis than did placebo in participants with metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, according to data from the phase 3 ESSENCE trial. Although the trial is ongoing, Phil Newsome (London, UK) presented data from the prespecified

Section snippets Mirikizumab for Crohn's diseaseMirikizumab, a monoclonal antibody targeting IL-23p19, shows promise for patients with moderately-to-severely active Crohn's disease, according to the VIVID-1 phase 3 trial. Marc Ferrante and colleagues randomly assigned patients who had a previous inadequate response, loss of response, or intolerance to one or more therapies to receive either mirikizumab

No Abstract

No Abstract

BackgroundClinically significant liver fibrosis is associated with future adverse events in patients with steatotic liver disease. We designed a software tool for detection of clinically significant liver fibrosis in primary care. MethodsIn this prospective cohort study, we developed and validated LiverPRO using six independent cohorts from Denmark, Germany, and England that included patients from

To establish a consensus on the definition and management of idiopathic gastroparesis, international experts (selected by neurogastroenterology and motility societies and initiated by the Rome Foundation) devised 144 statements using the Delphi method, with at least 80% agreement required. This consensus defined idiopathic gastroparesis as the presence of symptoms associated with delayed gastric emptying

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes. Beyond the implications of MASLD for liver health, it is also associated with cardiovascular and vascular dysfunction. Although the many shared risk factors

No Abstract

BackgroundBlood loss and subsequent red blood cell transfusions are common in liver surgery. Hypovolaemic phlebotomy is associated with decreased red blood cell transfusion in observational studies. This trial aimed to investigate whether hypovolaemic phlebotomy is superior to usual care in reducing red blood cell transfusions in patients undergoing liver resection. MethodsPRICE-2 was a multicentre

There is growing interest in the potential exploitation of the gut microbiome as a diagnostic tool in medicine, but evidence supporting its clinical usefulness is scarce. An increasing number of commercial providers offer direct-to-consumer microbiome diagnostic tests without any consensus on their regulation or any proven value in clinical practice, which could result in considerable waste of individual

No Abstract

No Abstract

BackgroundThere is a need for efficacious therapies for patients with Crohn's disease that are better tolerated and more durable than available treatments. We aimed to evaluate the efficacy and safety of filgotinib, an oral Janus kinase 1 preferential inhibitor, for treating Crohn's disease. MethodsThis phase 3, double-blind, randomised, placebo-controlled trial was conducted in 371 centres in 39 countries

Approximately half of patients with Crohn's disease require ileocolonic resection. Of these, 50% will subsequently have endoscopic disease recurrence within 1 year. We aimed to evaluate the efficacy and safety of vedolizumab to prevent postoperative recurrence of Crohn's disease.

No Abstract

No Abstract

Laparoscopic surgery is increasingly used for rectal cancer, but the long-term oncological outcomes for low rectal cancer have not been fully established. We aimed to evaluate the 3-year survival outcomes of laparoscopic surgery versus open surgery in the treatment of low rectal cancer.

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Section snippets Tranexamic acid not recommended for liver cancer surgeryTranexamic acid does not reduce bleeding and increases major complications in liver cancer surgery, according to new findings from the HeLiX trial. Paul Karanicolas and colleagues randomly assigned patients undergoing liver resection for cancer to receive either tranexamic acid (n=619) or matching placebo (n=626) beginning at

No Abstract

No Abstract

BackgroundExpanding antiviral therapy to people with chronic hepatitis B virus (HBV) infection who are ineligible to receive treatment under current international criteria has been increasingly debated. Evidence to support this approach is scarce, especially in Africa. We aimed to address this knowledge gap by analysing the clinical outcomes of people with chronic hepatitis B in The Gambia who were

Diet is a cornerstone in the management of irritable bowel syndrome (IBS). There is evidence of efficacy across the spectrum of dietary management strategies, including some supplements (eg, specific fibres), foods, and whole diets (eg, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols [known as the low-FODMAP diet]). Whole-diet interventions, in particular those

Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction characterised by symptoms of abdominal pain, occurring at least 1 day per week, and a change in stool frequency or form. Individuals with IBS are usually subtyped according to their predominant bowel habit, which is used to direct symptom-based treatment. However, this approach is probably an oversimplification of a complex

Section snippets ContributorsAll authors provided clinical care to the patient and contributed to the final manuscript. Written informed consent for publication was obtained from the patient. Declaration of interestsWe declare no competing interests.

IMU-856 is an orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6), a protein that serves as a transcriptional regulator of bowel epithelium regeneration. We aimed to evaluate the safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856 in healthy participants and in patients with coeliac disease.